Low-dose Colchicine for Chronic Kidney Disease

(RESOLVE-CKD Trial)

This trial aims to determine if low-dose Colchicine, an anti-inflammatory medication, can slow calcium buildup in the heart arteries of people with chronic kidney disease. Participants will receive either this medication plus their usual care or just their usual care, and the trial will last for 24 months. Researchers will also examine other health aspects, such as heart valve changes, bone health, and the treatment's impact on daily life. Individuals with chronic kidney disease who have existing heart artery calcification and can manage their usual activities might be suitable for this trial. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant medical advancements.

Research has shown that low-dose colchicine is promising in terms of safety across various situations. One study found that colchicine did not cause more serious side effects than a placebo, indicating it was generally well-tolerated. Another study demonstrated that it helped reduce heart-related problems without raising the risk of dangerous complications. Colchicine is also approved for reducing heart issues in people with heart disease, indicating a safety record in certain conditions. While these findings are encouraging, safety can vary based on individual health factors.¹²³⁴⁵

Unlike the standard treatments for chronic kidney disease, which often focus on blood pressure control and diabetes management, low-dose Colchicine (LoDoCo) targets inflammation, a key player in the progression of kidney damage. Researchers are excited about this approach because Colchicine has a long history of use in treating gout and other inflammatory conditions, suggesting it might be a safe and effective option for kidney disease too. Additionally, its established safety profile and oral administration make it a practical addition to current treatment regimens.

Studies have shown that low-dose colchicine (LoDoCo) can reduce the risk of heart problems, such as heart attacks and strokes. Research indicates that LoDoCo lowers the chance of these events by about 30% compared to not taking it. For individuals with long-term coronary artery disease, LoDoCo has reduced major heart-related issues by 23-31%. It also appears to decrease inflammation around the heart, which plays a crucial role in heart disease. This trial will assess the potential benefits of LoDoCo for individuals with chronic kidney disease, particularly those with heart problems. Participants will receive either LoDoCo in addition to usual care or usual care alone.²⁶⁷⁸⁹